Back to results
US RE46,604 E1Granted
Treatment of circadian rhythm disorders
AssigneeVanda Pharmaceuticals Inc.
InventorsMarlene Michelle Dressman, John Joseph Feeney, Louis William Licamele, Mihael H. Polymeropoulos
Life of this patent
Estimating the term…
Abstract
Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.
Claims8
A method of entraining a patient suffering from Non-24 to a 24 hour sleep-wake cycle in which the patient awakens at or near a target wake time following a daily sleep period of approximately 7 to 9 hours, and maintaining said 24 hour sleep-wake cycle said method comprising:
- treating the patient by orally administering to the patient 20 mg of tasimelteon once daily before a target bedtime.
Dependencies are inferred from the claim text.